<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03013218</url>
  </required_header>
  <id_info>
    <org_study_id>AT148001</org_study_id>
    <nct_id>NCT03013218</nct_id>
  </id_info>
  <brief_title>A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma</brief_title>
  <official_title>A Phase 1, Dose Escalation Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexo Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexo Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1, dose escalation study of ALX148 in patients with advanced solid tumors and
      lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose,
      dose-escalation, safety, PK, and PD study of ALX148. The phase 1 protocol will have 2 parts:
      a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part
      2 will include an initial dose escalation portion followed by a dose expansion portion.
      Approximately 142 adult patients are expected to be enrolled in the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (Number of participants with a DLT)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of participants with a DLT</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>Advanced Cancer</condition>
  <condition>NonHodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>ALX148</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Part 1 Dose Escalation: ALX148 infusions will be administered weekly or every two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX148 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions administered every three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX148 + Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with trastuzumab infusions administered every three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX148 + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with rituximab infusions administered once weekly for 4 doses followed by once monthly for 8 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALX148</intervention_name>
    <description>ALX148</description>
    <arm_group_label>ALX148</arm_group_label>
    <arm_group_label>ALX148 + Pembrolizumab</arm_group_label>
    <arm_group_label>ALX148 + Trastuzumab</arm_group_label>
    <arm_group_label>ALX148 + Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Keytruda</description>
    <arm_group_label>ALX148 + Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Herceptin</description>
    <arm_group_label>ALX148 + Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituxan</description>
    <arm_group_label>ALX148 + Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy;
             or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is
             available..

          -  Adequate Bone Marrow Function.

          -  Adequate Renal &amp; Liver Function.

          -  Adequate Performance Status

        Exclusion Criteria:

          -  Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring
             steroids.

          -  Previous high-dose chemotherapy requiring allogenic stem cell rescue.

          -  Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophia Randolph, MD, PhD</last_name>
    <phone>650-466-7125</phone>
    <email>info@alexotherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philip Fanning, PhD</last_name>
    <phone>650-466-7125</phone>
    <email>info@alexotherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt O'Hern</last_name>
      <phone>720-848-0523</phone>
      <email>matthew.ohern@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Hotchkiss, MPH</last_name>
      <phone>203-737-5228</phone>
      <email>caroline.hotchkiss@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Annese</last_name>
      <phone>617-724-6634</phone>
      <email>rannese2@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>START-Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Estkowski, BS, CCRP</last_name>
      <phone>616-954-5554</phone>
      <email>kathy.estkowski@start.stoh.com</email>
    </contact>
    <contact_backup>
      <last_name>Yvette C Cole, RN, BSN, OCN</last_name>
      <phone>616-954-5554</phone>
      <email>yvette.cole@start.stoh.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Peters, CCRC</last_name>
      <phone>206-606-7551</phone>
      <email>phase1@u.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukyung Shin</last_name>
      <phone>82-2-6072-5220</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>CD47</keyword>
  <keyword>SIRPÎ±</keyword>
  <keyword>ALX148</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

